Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Filociclovir is a second-generation methylene cyclopropane compound and a purine nucleoside analogue with broad-spectrum antiviral activity. It acts primarily as a DNA-directed DNA polymerase inhibitor and ganciclovir kinase inhibitor. Filociclovir is structurally related to guanosine and functions by inhibiting viral replication through interference with viral DNA polymerases. It has demonstrated potent in vitro activity against human cytomegalovirus (HCMV), being approximately ten times more effective than ganciclovir without increased cytotoxicity. The drug is under development for the treatment of cytomegalovirus infections and has also shown activity against other herpesviruses such as HHV-6 and HHV-8[1][3][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on filociclovir.